Leukemia News

Latest Lymphoma / Leukemia News From Medical News Today.

Total news: 25
Last news: August 30, 2007 07:00:00

Latest Leukemia News From News-Medical.Net

Total news: 10
Last news: August 30, 2007 09:29:00

A new study suggests that an experimental drug being tested for the treatment of multiple sclerosis and to prevent organ rejection might also help people with certain deadly forms of chronic and acute leukemia. - [Read more]

In the September 15th issue of Genes & Development, Drs. Richard T. Williams, Willem den Besten, and Charles J. Sherr at Howard Hughes Medical Institute, St. Jude Childrens Research Hospital in Memphis TN, lend new insights into how an aggressive form of acute lymphoblastic leukemia (ALL) develops, and how sensitivity to the targeted chemotherapeutic drug, imatinib, can be diminished through interactions between tumor cells and the host microenvironment. - [Read more]

The relationship between rheumatoid arthritis (RA), an autoimmune disease marked by chronic inflammation of the joints and tissue surrounding vital organs, and the incidence of cancer is complicated. - [Read more]

Lorus Therapeutics Inc. [click link for full article] - [Read more]

Cephalon, Inc. announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development granted orphan drug designation for the companys investigational therapy, TREANDA (bendamustine HCl), for the treatment of chronic lymphocytic leukemia (CLL). - [Read more]

Results of a study by investigators at St. Jude Childrens Research Hospital provide strong evidence for why the drug imatinib (Gleevec), which has revolutionized the treatment of chronic myelogenous leukemia (CML), is often unable to prevent relapse of a particularly aggressive form of acute lymphoblastic leukemia (ALL). - [Read more]

CuraGen Corporation (Nasdaq: CRGN) and TopoTarget A/S (Copenhagen Stock Exchange: TOPO) announced today the initiation of patient dosing in a Phase I/II clinical trial evaluating belinostat (PXD101), a histone deacetylase (HDAC) inhibitor, in combination with the anthracycline idarubicin for the treatment of Acute Myeloid Leukemia (AML). The trial is being conducted at multiple sites in the European Union. [click link for full article] - [Read more]

System overload: infusion of IgG helps clear therapeutic and imaging antibodies from the circulationThe use of monoclonal IgG antibodies attached to toxins or radioactive substances for treating and imaging cancer is currently limited by the ability of IgG to remain in the blood for a long time because this decreases the tumor-to-background contrast and increases normal tissue toxicity. [click link for full article] - [Read more]

In a new study, Danilo Perrotti and colleagues from Ohio State University, Columbus, show that treatment with a drug known as FTY720 prevents disease in a mouse model of many leukemias caused by the cancer protein BCR-ABL (nearly all cases of blast crisis chronic myeloid leukemia [CML-BC] and some cases of acute lymphocytic leukemia [ALL]). [click link for full article] - [Read more]

The study, which appears in the August issue of Molecular & Cellular Proteomics, could lead to a better understanding of how proteins inside a specific type of cell work together and may pave the way for future detailed studies of how proteins work in other types of cells. - [Read more]

Rice University chemists have found a way to package some of natures most powerful radioactive particles inside DNA-sized tubes of pure carbon -- a method they hope to use to target tiny tumors and even lone leukemia cells. - [Read more]

In a new study, Danilo Perrotti and colleagues from Ohio State University, Columbus, show that treatment with a drug known as FTY720 prevents disease in a mouse model of many leukemias caused by the cancer protein BCR-ABL (nearly all cases of blast crisis chronic myeloid leukemia [CML-BC] and some cases of acute lymphocytic leukemia [ALL]). - [Read more]

Rapamycin isnt your ordinary potential anti-cancer drug…It had a long and somewhat exotic history before undergoing preclinical (laboratory-based) studies at St. Jude as part of a national Pediatric Preclinical Testing Program (PPTP) investigation of its anticancer activity. - [Read more]

Children with mediastinal masses - tumors in their chest outside the lungs - are at special risk for developing breathing problems when they undergo anesthesia. These young patients are of special concern to clinicians who must anesthetize them as part of their medical treatment. - [Read more]

Pharmion Corporation (Nasdaq: PHRM), along with its collaborator MethylGene Inc. (TSX: MYG), today announced that the U.S. Food and Drug Administration (FDA) has designated the Companies histone deacetylase (HDAC) inhibitor, MGCD0103, as an Orphan Drug for the treatment of Hodgkins lymphoma in the United States. [click link for full article] - [Read more]

Individuals with chronic myeloid leukemia (CML) are treated first with a drug known as imatinib (Gleevec), which targets the protein known to cause the cancer (BCR-ABL). If their disease returns, because BCR-ABL mutants emerge that are resistant to the effects of imatinib, individuals are treated with a drug known as dasatinib (SPRYCEL), which targets BCR-ABL in a different way. [click link for full article] - [Read more]

VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced that it had accrued a total of 85 patients to the pivotal Phase II trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in previously untreated elderly patients with de novo poor-risk acute myelogenous leukemia (AML). Alan Kessman, Chief Executive Officer said, "We are extremely pleased to have reached this milestone in the pivotal Phase II trial of our lead anticancer agent. [click link for full article] - [Read more]

Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced the initiation of patient enrollment in a Phase 1, open-label, multi-center study of the Companys novel antifolate PDX (pralatrexate) with vitamin B12 and folic acid supplementation in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). [click link for full article] - [Read more]

Xenomics, Inc. (the "Company") (Pink Sheets: XNOM; FWB: XE7) a developer of next-generation medical DNA diagnostic technologies, announced today that its first diagnostic test developed for stratification of patients with Acute Myeloid Leukemia (AML) has been implemented at CLIA approved BRT Laboratories Inc. in Baltimore, Maryland, and is available for clinicians. [click link for full article] - [Read more]

A new study suggests that acute leukemia patients whose cancer cells show a genetic change that usually predicts a swift return of the disease following remission may remain disease-free longer when given aggressive therapy.The findings apply to people with acute myeloid leukemia (AML) whose cancer cells have normal-looking chromosomes and a gene mutation called MLL-PTD. [click link for full article] - [Read more]